Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays

Physiological Genomics

Volumn 11, Issue , 2003, Pages 45-52

  Sarang, Satinder S ^a   Yoshida, Takumi ^a   Cadet, Rodolphe ^a   Valeras, Andrew S ^a   Jensen, Roderick V ^a   Gullans, Steven R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Galanin; Oxidative stress

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BROMOCRIPTINE; DITHRANOL; ERYTHROMYCIN; FLUNISOLIDE; KANAMYCIN; LITHIUM; MECLOZINE; MEGESTROL; METHAZOLAMIDE; MEXILETINE; MINOCYCLINE; NALTREXONE; NEUROPROTECTIVE AGENT; NIFEDIPINE; NIMODIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; PRAMOCAINE; RETINOL; SCOPOLAMINE; SOTALOL; SULFACETAMIDE; SULINDAC; TIMOLOL; TRAZODONE; TROLEANDOMYCIN; UNINDEXED DRUG; VERAPAMIL; HYDROGEN PEROXIDE; OXIDIZING AGENT;

ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DNA MICROARRAY; DOWN REGULATION; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; GENE TARGETING; HUMAN; HUMAN CELL; NERVE CELL; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROPROTECTION; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; UPREGULATION; BIOASSAY; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; NEUROBLASTOMA; PATHOLOGY;

BIOLOGICAL ASSAY; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; HYDROGEN PEROXIDE; MECLIZINE; MEGESTROL; METHAZOLAMIDE; NEUROBLASTOMA; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDANTS; SULINDAC; TUMOR CELLS, CULTURED; VERAPAMIL; VITAMIN A;

EID: 0037195201     PISSN: 15312267     EISSN: None     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00064.2002     Document Type: Article

References (62)

1. Abe K, Morita S, Kikuchi T, and Itoyama Y. Protective effect of a novel free radical scavenger, OPC-14117, on wobbler mouse motor neuron disease. J Neurosci Res 48: 63-70, 1997.
2. Bach UC, Baiersdorfer M, Klock G, Cattaruzza M, Post A, and Koch-Brandt C. Apoptotic cell debris and phosphatidylserine-containing lipid vesicles induce apolipoprotein J (clusterin) gene expression in vital fibroblasts. Exp Cell Res 265: 11-20, 2001.
3. Barry CE III, Slayden RA, Sampson AE, and Lee RE. Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochem Pharmacol 59: 221-231, 2000.
4. Blass JP. Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res 66: 851-856, 2001.
5. Bogdanov MB, Ramos LE, Xu Z, and Beal MF. Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis. J Neurochem 71: 1321-1324, 1998.
6. Bowling AC, Barkowski EE, McKenna-Yasek D, Sapp P, Horvitz HR, Beal MF, and Brown RH Jr. Superoxide dismutase concentration and activity in familial amyotrophic lateral sclerosis. J Neurochem 64: 2366-2369, 1995.
7. 2) increases the steady-state mRNA levels of collagenase/MMP-1 in human dermal fibroblasts. Free Radic Biol Med 22: 515-524, 1997.
8. Butte AJ, Ye J, Haring HU, Stumvoll M, White MF, and Kohane IS. Determining significant fold differences in gene expression analysis. Pac Symp Biocomput: 6-17, 2001.
9. Butterfield DA, Howard BJ, and LaFontaine MA. Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease. Curr Med Chem 8: 815-828, 2001.
10. Chang AY. Megestrol acetate as a biomodulator. Semin Oncol 25: 58-61, 1998.
11. Choi P, Golts N, Snyder H, Chong M, Petrucelli L, Hardy J, Sparkman D, Cochran E, Lee JM, and Wolozin B. Co-association of parkin and alpha-synuclein. Neuroreport 12: 2839-2843, 2001.
12. Cookson MR and Shaw PJ. Oxidative stress and motor neurone disease. Brain Pathol 9: 165-186, 1999.
13. Cornelli U, Terranova R, Luca S, Cornelli M, and Alberti A. Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr 131: 3208-3211, 2001.
14. Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, Schoenfeld DA, Hosler BA, Horvitz HR, and Brown RH. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 41: 210-221, 1997.
15. Cursio R, Mari B, Louis K, Rostagno P, Saint-Paul MC, Giudicelli J, Bottero V, Anglard P, Yiotakis A, Dive V, Gugenheim J, and Auberger P. Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J 16: 93-95, 2002.
16. Debouck C and Goodfellow PN. DNA microarrays in drug discovery and development. Nat Genet 21: 48-50, 1999.
17. Dumont P, Burton M, Chen QM, Gonos ES, Frippiat C, Mazarati JB, Eliaers F, Remacle J, and Toussaint O. Induction of replicative senescence biomarkers by sublethal oxidative stresses in normal human fibroblast. Free Radic Biol Med 28: 361-373, 2000.
18. Fassina G, Ferrari N, Brigati C, Benelli R, Santi L, Noonan DM, and Albini A. Tissue inhibitors of metalloproteases: regulation and biological activities. Clin Exp Metastasis 18: 111-120, 2000.
19. Gerhold D, Lu M, Xu J, Austin C, Caskey CT, and Rushmore T. Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. Physiol Genomics 5: 161-170, 2001.
20. Giannakopoulos P, Kovari E, French LE, Viard I, Hof PR, and Bouras C. Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study. Acta Neuropathol (Berl) 95: 387-394, 1998.
21. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, and Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985-989, 2000.
22. G-nitro-Larginine methyl ester-induced hypertension: modulation of proinflammatory signals. Hypertension 36: 103-109, 2000.
23. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, and Hall ED. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39: 147-157, 1996.
24. Gutmann DH, Wu YL, Hedrick NM, Zhu Y, Guha A, and Parada LF. Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes. Hum Mol Genet 10: 3009-3016, 2001.
25. Gwinn-Hardy K and Farrer M. Parkinson's genetics: an embarrassment of riches. Ann Neurol 51: 7-8, 2002.
26. Hake AM and Farlow MR. New concepts in the drug therapy of Alzheimer's disease. Expert Opin Pharmacother 2: 1975-1983, 2001.
27. Han X, Sun Y, Scott S, and Bleich D. Tissue inhibitor of metalloproteinase-1 prevents cytokine-mediated dysfunction and cytotoxicity in pancreatic islets and beta-cells. Diabetes 50: 1047-1055, 2001.
28. Hayward LJ, Rodriguez JA, Kim JW, Tiwari A, Goto JJ, Cabelli DE, Valentine JS, and Brown RH Jr. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial ALS. J Biol Chem, 2002.
29. Holmes FE, Mahoney S, King VR, Bacon A, Kerr NC, Pachnis V, Curtis R, Priestley JV, and Wynick D. Targeted disruption of the galanin gene reduces the number of sensory neurons and their regenerative capacity. Proc Natl Acad Sci USA 97: 11563-11568, 2000.
30. Hou XE, Lundmark K, and Dahlstrom AB. Cellular reactions to axotomy in rat superior cervical ganglia includes apoptotic cell death. J Neurocytol 27: 441-451, 1998.
31. Hsiao LL, Jensen RV, Yoshida T, Clark KE, Blumenstock JE, and Gullans SR. Correcting for signal saturation errors in the analysis of microarray data. Biotechniques 32: 330-332, 334, 336, 2002.
32. Hurko O and Walsh FS. Novel drug development for amyotrophic lateral sclerosis. J Neurol Sci 180: 21-28, 2000.
33. Junn E and Mouradian MM. Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett 320: 146-150, 2002.
34. Kaal EC, Vlug AS, Versleijen MW, Kuilman M, Joosten EA, and Bar PR. Chronic mitochondrial inhibition induces selective motoneuron death in vitro: a new model for amyotrophic lateral sclerosis. J Neurochem 74: 1158-1165, 2000.
35. Klaidman LK, Mukherjee SK, and Adams JD Jr. Oxidative changes in brain pyridine nucleotides and neuroprotection using nicotinamide. Biochim Biophys Acta 1525: 136-148, 2001.
36. Konta T, Xu Q, Furusu A, Nakayama K, and Kitamura M. Selective roles of retinoic acid receptor and retinoid x receptor in the suppression of apoptosis by all-trans-retinoic acid. J Biol Chem 276: 12697-12701, 2001.
37. Liesi P, Wright JM, and Krauthamer V. BAPTA-AM and ethanol protect cerebellar granule neurons from the destructive effect of the weaver gene. J Neurosci Res 48: 571-579, 1997.
38. Lindskog S. Structure and mechanism of carbonic anhydrase. Pharmacol Ther 74: 1-20, 1997.
39. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, and Brown EL. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14: 1675-1680, 1996.
40. Ludolph AC. Animal models for motor neuron diseases: research directions. Neurology 47: S228-232, 1996.
41. Ma W, Zheng WH, Belanger S, Kar S, and Quirion R. Effects of amyloid peptides on cell viability and expression of neuropeptides in cultured rat dorsal root ganglion neurons: a role for free radicals and protein kinase C. Eur J Neurosci 13: 1125-1135, 2001.
42. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, and Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56: 127-129, 2001.
43. McCord JM. The evolution of free radicals and oxidative stress. Am J Med 108: 652-659, 2000.
44. Misonou H, Morishima-Kawashima M, and Ihara Y. Oxidative stress induces intracellular accumulation of amyloid β-protein (Aβ) in human neuroblastoma cells. Biochemistry 39: 6951-6959, 2000.
45. Mitsumoto H. Clinical trials: present and future. Amyotroph Lateral Scler Other Motor Neuron Disord 2, Suppl 1: S10-S14, 2001.
46. Moreno-Manzano V, Ishikawa Y, Lucio-Cazana J, and Kitamura M. Suppression of apoptosis by all-trans-retinoic acid. Dual intervention in the c-Jun n-terminal kinase-AP-1 pathway. J Biol Chem 274: 20251-20258, 1999.
47. Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58: 179-185, 2002.
48. Murray JB. Psychophysiological aspects of motion sickness. Percept Mot Skills 85: 1163-1167, 1997.
49. O'Meara G, Coumis U, Ma SY, Kehr J, Mahoney S, Bacon A, Allen SJ, Holmes F, Kahl U, Wang FH, Kearns IR, Ove-Ogren S, Dawbarn D, Mufson EJ, Davies C, Dawson G, and Wynick D. Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons. Proc Natl Acad Sci USA 97: 11569-11574, 2000.
50. Pasinelli P, Borchelt DR, Houseweart MK, Cleveland DW, and Brown RH Jr. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci USA 95: 15763-15768, 1998.
51. Pekoe G, Van Dyke K, Peden D, Mengoli H, and English D. Antioxidation theory of non-steroidal anti-inflammatory drugs based upon the inhibition of luminol-enhanced chemiluminescence from the myeloperoxidase reaction. Agents Actions 12: 371-376, 1982.
52. Reis BY, Butte AS, and Kohane IS. Extracting knowledge from dynamics in gene expression. J Biomed Inform 34: 15-27, 2001.
53. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, and Brown PO. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227-235, 2000.
54. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, and Weinstein JN. A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244, 2000.
55. Silani V, Braga M, Cardin V, and Scarlato G. The pathogenesis of ALS: implications for treatment strategies. Neurol Neurochir Pol 35: 25-39, 2001.
56. Tallini G and Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 8: 345-354, 2001.
57. Viard I, Wehrli P, Jornot L, Bullani R, Vechietti JL, Schifferli JA, Tschopp J, and French LE. Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. J Invest Dermatol 112: 290-296, 1999.
58. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, and Koo EH. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414: 212-216, 2001.
59. Wehrli P, Charnay Y, Vallet P, Zhu G, Harmony J, Aronow B, Tschopp J, Bouras C, Viard-Leveugle I, French LE, and Giannakopoulos P. Inhibition of post-ischemic brain injury by clusterin overexpression. Nat Med 7: 977-979, 2001.
60. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, and Paull KD. An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349, 1997.
61. Wodicka L, Dong H, Mittmann M, Ho MH, and Lockhart DJ. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 15: 1359-1367, 1997.
62. Zhang Y, Dawson VL, and Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 7: 240-250, 2000.